Aggregated News

A new survey of over 100 European clinical geneticists reveals general opposition to the way in which direct to consumer (DTC) genetic testing is delivered by commercial providers.

DTC genetic testing is a contentious area around the world with ongoing debate about how scientifically valid, clinically useful and ethically appropriate they are. Writing in the journal Genome Medicine, researchers report that 86% of their respondents were aware of DTC genetic testing, the most frequently mentioned providers being 23andme, deCODE and Navigenics.

Almost all the geneticists were opposed to any form of DTC testing for medical conditions that were not preventable or treatable, or for serious disorders. Most were also opposed to DTC testing for presymptomatic predictive testing for disorders with medium or high penetrance (50% and above), but 40% did not object to DTC genetic carrier testing. However, most said they would be willing to see patients who were concerned about DTC genetic testing results, and 44% has already done so.

84% did not agree with the idea of medical supervision being provided by phone to patients without an...